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A Potential Role of
Indoleamine 2,3-
Dioxygenase–Speciﬁc T cells
in Leishmania Vaccination
Tot h eEditor—In a recent issue of
the Journal, Makala and colleagues ele-
gantly describe that indoleamine 2,3-
dioxygenase (IDO) is increased in lymph
nodes in cutaneous Leishmania major
infection [1]. IDO is implicated in sup-
pressing T-cell immunity to parasite an-
tigens, and IDO inhibition reduced local
inﬂammation and parasite burdens. IDO
is an immunoregulatory enzyme im-
plicated in immunity under normal and
pathological settings [2], and provides
a potential mechanism for the develop-
ment of dendritic cell (DC)–mediated
T-cell tolerance [3]. IDO
1 DCs inhibit
T-cell proliferation due to tryptophan
depletion and accumulation of toxic
tryptophan metabolites [2]. IDO may be
relevant to the outcome of immuno-
therapy as an inﬂammation-induced
counter-regulatory mechanism, and may
be induced by both type I and II inter-
ferons, which are found at sites of im-
mune activation and inﬂammation [4].
Counter-regulatory responses are important
as they help to limit the intensity and extent
of immune responses, which otherwise
could cause dangerous damage to the host.
However, with regard to vaccination,
counter-regulatory responses antagonize the
ability to create an intense immune re-
sponse against the target. The ﬁndings by
Makala et al support a counter-regulatory
role for IDO that beneﬁts the pathogen,
not the host. In this regard, an interesting
aspect of IDO is that systemic inactivation
at the organism level, either pharmacologi-
cally or genetically, does not appear to cause
autoimmunity [5]. IDO may not be
involved in tolerance to self, but rather
in tolerance to nonself antigens, where
immune non-responsiveness may be
important, for example, fetal antigens [5].
Induction of IDO
1 tolerogenic DCs occurs
during infection of DCs with viruses and
intracellular pathogens, such as Listeria
monocytogenes.
We have described that peptides com-
prised in the IDO protein sequence are
spontaneously recognized by cytotoxic T
cells in cancer patients [6] and healthy
individuals [7]. IDO-reactive T cells
recognized and killed IDO-expressing
cells, for example, tumor cells or regu-
latory DCs. Importantly, the presence
of such IDO-speciﬁc CD8
1 Tc e l l s
boosted T-cell immunity against viral or
tumor-associated antigens by eliminating
IDO
1 suppressive cells, thereby directly
targeting the IDO-dependent counter-
regulatory pathway. The direct killing of
IDO-expressing cells diminished IDO-
mediated suppression of effector T cells
and decreased the local Treg suppression
byreprogrammingTregstoacquireapro-
inﬂammatoryTh17-likephenotypeunder
inﬂuence of increased interleukin-6 pro-
duction. It was recently described that
Treg cells can undergo rapid reprogram-
ming into activated T-helper cells after
vaccination in combination with toll-like
receptor 9 [8]. The conversion of the Tregs
was suppressed by tumor-induced IDO
expression. The pharmacologic inhibition
of IDO restored Treg cell reprogramming,
vaccine efﬁcacy, and antitumor CD8
1
T-cell responses. Thus, reprogramming of
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early CD8
1 T cell responses.
Finally, IDO
1 cells may be suppressive
by other means than IDO, for example,
arginase, PD-L1, or HLA-G. Hence, IDO-
speciﬁc T cells may reduce not only IDO-
mediated suppression but, in addition,
immune suppression mediated by IDO
1
regulatory cells. To examine the possible
effects (and/or side effects) of the induc-
tion of IDO-speciﬁc T cells, a phase I
vaccination study is ongoing at the
Center for Cancer Immune Therapy,
Copenhagen University Hospital, in
which patients with non-small-cell lung
cancer are vaccinated with an IDO-
derived peptide with Montanide adjuvant
(www.clinicaltrials.gov; NCT01219348).
Different species of Leishmania are
responsible for cutaneous, mucocutane-
ous, or visceral leishmaniasis infections
in millions of people. Adverse reactions
caused by antileishmanial drugs, emer-
gence of resistance, and lack of a vaccine
have motivated the search for new
therapeutic options to control this dis-
ease. There have been notable advances
in molecular diagnostics, in the un-
derstanding of host immune responses
to infection, and in vaccine de-
velopment. The fact that IDO may be
involved in tolerance to nonself antigens
might have major implications for IDO-
based immune therapy as boosting im-
munity to neoantigens, but not normal
self-antigens, by the activation of IDO-
speciﬁc T cells is very attractive. As de-
scribed by Makala et al, IDO suppresses
adaptive immunity, suggesting that in
the clinical setting, the targeting of IDO
could have synergistic effects in Leish-
mania vaccine development. Thus, the
induction of IDO-speciﬁc immune re-
sponses by therapeutic measures could
function synergistically with additional
immune therapy. Almost any successful
immune therapy strategy aims at inducing
immu-nological activation and in-
ﬂammation. Since IDO-expressing cells
might antagonize the desired effects of
other immunotherapeutic approaches,
targeting IDO-expressing cells by
vaccination would be easily implementable
and compatible with such therapeutic
measures. It should ﬁnally be noted that it
is premature to assume that targeting IDO-
expressing cells (using enzyme inhibitors
or IDO-speciﬁc vaccines) will not induce
autoimmunity (or other side effects). This
needs to be considered in a clinical setting.
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